RHINOX®

ONCE A SEASON THERAPY  FOR NASAL ALLERGIES

About Us

Cyrano was founded by Ira Sanders, M.D., a board certified Otolaryngologist who

began experimenting with botulinum toxin for rhinitis in 1992.  He was a faculty member

at the Mount Sinai School of Medicine for 15 years where he performed award

winning research funded by five major grants from the National Institutes of Health.

He has 7 awarded patents, two of which have been successfully commercialized.

Within the past five years, he has founded three companies which have

successfully attracted angel and venture capital, as well as NIH and NJ

research grant funding.

 

Executive Leadership

 

Shawn O'Brien, the former CEO of one of the few companies producing FDA

approved botulinum toxin provides executive leadership. 

 

Mark Funston, the former CFO of Medscape/WebMD advises on finance issues.

 

Operations and Administration

 

Alex Paris, a student at the Wharton School of Business, wrote the initial business

plan and continues to provide organizational and strategic advice.

 

Asif Amirali, M.D., has ten years experience in research and medical based

startup companies.

 

Regulatory Affairs and Clinical Trials

 

Marilyn R. Carlson, D.M.D., M.D., RAC, President of Entremedica Inc, 

consults on clinical and regulatory issues.

 

Joseph F. Sgherza has over 20 years of experience in conducting clinical trials all

over the world.

 

Medical and Scientific Advisors

 

Andrew Blitzer, M.D., D.D.S., F.A.C.S. is an internationally known Otolaryngologist

and pioneer in the use of botulinum toxin in medicine. He is perhaps the only

American physician to have performed a clinical trial of botulinum toxin for rhinitis.

 

Peter Catalano, M.D., F.A.C.S. is Chairman of Otolaryngology at St Elizabeth's

Hospital in Boston. Dr Catalano has extensive experience in using botulinum toxin to treat rhinitis.